Printer Friendly

Ablynx and Sanofi enter strategic collaboration to develop Nanobody product candidates.

M2 EQUITYBITES-July 20, 2017-Ablynx and Sanofi enter strategic collaboration to develop Nanobody product candidates


Ablynx NV (EBR: ABLX) has entered into a research collaboration and global exclusive licensing agreement with Sanofi SA (EPA: SAN) to develop and commercialise Nanobody-based therapeutics to treat various immune-mediated inflammatory diseases, the Belgium-based biopharmaceutical company announced on Thursday.

As a result of the agreement, Sanofi will gain access to specific Ablynx Nanobodies and Ablynx's scientists and proprietary Nanobody platform.

Sanofi will have exclusive global rights to certain multi-specific Nanobodies against selected targets. The company will also have options for similar rights to additional targets, for a total of eight potential Nanobody product candidates.

Ablynx will receive an upfront payment of EUR23m, comprised of licence and option fees. The company will also receive research funding, which is estimated to amount to EUR8m for the initially selected targets. Sanofi will pay Ablynx further option exercise fees and research funding upon exercise of options to additional targets.

Under the terms of the agreement, Sanofi will be responsible for the development, manufacturing and commercialisation of any products resulting from the agreement. Through development, regulatory and commercial milestone payments, Ablynx could receive up to EUR2.4bn, as well as tiered royalties up to low double digits on the net sales of any products originating from the collaboration.

((Comments on this story may be sent to

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 20, 2017
Previous Article:FNB Corporation announces series E preferred stock dividend of USD18.13 per share for quarter.
Next Article:Regulus anticipates USD37.3m from public offering of common shares.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters